<DOC>
	<DOC>NCT00430495</DOC>
	<brief_summary>This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha (TNFa) antagonist due to lack of efficacy.</brief_summary>
	<brief_title>A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>1. Rheumatoid arthritis (RA) satisfying American College of Rheumatology (ACR) diagnostic criteria with a disease history of at least one year 2. Male or female greater than or equal to (&gt;=)18years of age at time of informed consent 3. Active RA as defined by: &gt;=8 swollen joints (66joint count), &gt;=8 tender joints (68joint count), and Creactive protein (CRP) &gt;=10 milligram per liter (mg/L) (central laboratory) and/or erythrocyte sedimentation rate (ESR) &gt;= to 28 millimeter per hour (mm/h) 4. Failure of at least one TNFa antagonist therapy (previously or at the time of screening) as specified in the protocol 5. Other protocol defined inclusion criteria could apply 1. Any condition, including laboratory findings or findings in the medical history or pretrial assessments, that in the opinion of the Investigator constitutes a risk or a contraindication for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation 2. Treatment with biologics aiming at B cell modulation such as rituximab or belimumab within 2 years before study Day 1 3. Any previous treatment with anakinra (Kineret), abatacept (Orencia) or tocilizumab within 3 months before study Day 1 4. Use of etanercept (Enbrel) within 28 days before study Day 1, or of infliximab (Remicade) or adalimumab (Humira) within 60 days before study Day 1 5. Participation in any interventional clinical trial with an unapproved investigational therapy within the 3 months before the start of this study (or within 5 halflives of the investigated compound before study Day 1, whichever is longer) 6. Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>atacicept</keyword>
	<keyword>arthritis</keyword>
</DOC>